Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to 19.51%.

  • Mimedx's EBITDA Margin rose 62300.0% to 19.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.69%, marking a year-over-year decrease of 47700.0%. This contributed to the annual value of 16.87% for FY2024, which is 53300.0% up from last year.
  • According to the latest figures from Q3 2025, Mimedx's EBITDA Margin is 19.51%, which was up 62300.0% from 12.55% recorded in Q2 2025.
  • In the past 5 years, Mimedx's EBITDA Margin ranged from a high of 26.89% in Q2 2024 and a low of 15.79% during Q1 2022
  • Its 5-year average for EBITDA Margin is 6.14%, with a median of 11.9% in 2024.
  • As far as peak fluctuations go, Mimedx's EBITDA Margin soared by 277500bps in 2023, and later tumbled by -143500bps in 2025.
  • Quarter analysis of 5 years shows Mimedx's EBITDA Margin stood at 2.53% in 2021, then surged by 501bps to 15.21% in 2022, then increased by 17bps to 17.84% in 2023, then tumbled by -33bps to 11.9% in 2024, then surged by 64bps to 19.51% in 2025.
  • Its last three reported values are 19.51% in Q3 2025, 12.55% for Q2 2025, and 9.35% during Q1 2025.